Plus Therapeutics (PSTV) filed a registration statement Friday with the US Securities and Exchange Commission covering the potential sale of up to $100 million of its securities from time to time in one or more offerings.
The filing covers common and preferred stock, warrants, debt securities, depositary shares, stock purchase contracts, subscription rights and units.
Plus Therapeutics said it intends to use the net proceeds from the offering for general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments